AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Dow Chemical Sees Heavy Put Trading Ahead of Earnings Release
ByAinvest
Friday, Jun 27, 2025 11:31 pm ET1min read
Dow Chemical experienced heavy put volume, with 12,344 puts trading, or 3x expected. The most active strikes were the 7/25 weekly 25 puts and Dec-25 37.5 calls, with a total volume of near 11,200 contracts. The Put/Call Ratio was 5.27, and ATM IV was up over 3 points on the day. Earnings are expected on July 24th.
Dow Chemical (DOW) experienced significant put volume on Monday, June 19, 2025, with 12,344 puts trading, representing a threefold increase over expected levels. This heavy put volume, coupled with a high put/call ratio of 5.27 and a notable increase in implied volatility (ATM IV up over 3 points), suggests investor caution ahead of the company's earnings report scheduled for July 24, 2025 [1].The most active strikes were the 7/25 weekly 25 puts and Dec-25 37.5 calls, with a combined volume of nearly 11,200 contracts. This activity indicates that investors are positioning themselves for potential downward movement in the stock price, as evidenced by the high volume of put options, which are typically used to profit from a decline in the underlying asset's price.
Dow Chemical operates in various segments, including Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings, providing materials science solutions for diverse applications globally [2]. The company's extensive portfolio and international reach make it a significant player in the chemical industry.
Investors should closely monitor Dow Chemical's earnings report to gauge the company's performance and the market's reaction to the results. The heavy put volume and increased implied volatility suggest that investors are anticipating potential challenges or uncertainties that could impact the stock price.
References:
[1] https://finance.yahoo.com/quote/DOW/
[2] https://www.tradingview.com/news/reuters.com,2025-06-26:newsml_GNX8R7BBD:0-invivyd-announces-positive-full-phase-1-2-clinical-data-for-vyd2311-a-next-generation-covid-19-monoclonal-antibody-for-potential-use-as-a-non-vaccine-preventative-and-for-treatment-of-active-infection/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments

No comments yet